3BP has built a portfolio of preclinical development programs exclusively derived from internal discovery efforts. All four programs are aimed at theranostic combinations based on the same targeting molecule. The most advanced program targeting neurotensin receptor 1 in pancreatic cancer as well as other indications was recently out-licensed to Ipsen Pharma.

Peptidomimetic tracers. Cancer drug development at 3BP.